Capping Both Ends of an Antimicrobial Peptide Makes It Stronger but Less Selective Against Cancer

Adding chemical caps to both ends of the antimicrobial peptide tachyplesin I (N-terminal acetylation and C-terminal amidation) increased its cell-killing potency against tumor cells and made it resistant to enzymatic breakdown in human serum. However, the modifications also increased toxicity toward normal cells and red blood cells (hemolysis), presenting a double-edged sword for anticancer development.

In vitro study using MTT cell viability assays on tumor cell lines (A549, HeLa) and normal human cells (HEK293), plus hemolysis assays on human red blood cells. Proteolytic stability was tested by incubating modified and unmodified peptides in fresh human serum.

Antimicrobial peptides like tachyplesin I are promising anticancer candidates, but they break down too quickly in the bloodstream to be practical drugs. This study shows that simple chemical modifications can solve the stability problem — the modified peptide resisted degradation in human serum. The challenge is that the same modifications that make it more potent also make it less selective for cancer cells.

The stability-selectivity tradeoff demonstrated here is a central challenge in antimicrobial peptide drug development. While terminal modifications are a common strategy for improving peptide pharmacokinetics, this study illustrates why simple chemical capping alone may not be enough — future approaches may need to combine stability modifications with targeting strategies to preserve selectivity for cancer cells.

Entirely in vitro — no animal or human testing. Increased toxicity to normal cells is a significant concern that would need to be addressed before any clinical development. Specific IC50 values and fold-changes in cytotoxicity are not provided in the abstract.